A study, published recently in Clinical Cancer Research, has found that myeloma patients may be genetically predisposed to Velcade-induced peripheral neuropathy. Researchers carried out a genome-wide association study (GWAS) of over 370,000 single nucleotide polymorphisms (SNPs) in 469 myeloma patients treated with Velcade and dexamethasone prior to high-dose therapy and autologous stem cell transplantation in…Details
Minimal residual disease monitoring and immune profiling using second generation flow cytometry in elderlymultiple myeloma. Paiva B et al. Blood. 2016 Apr 26. pii: blood-2016-03-705319. [Epub ahead of print]. Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab. Postelnek J et al. AAPS J. 2016 Apr 26. [Epub…Details
Laboratory testing in monoclonal gammopathy of renal significance (MGRS). Leung N et al. Clin Chem Lab Med. 2016 Apr 23. pii: /j/cclm.ahead-of-print/cclm-2015-0994/cclm-2015-0994.xml. doi: 10.1515/cclm-2015-0994. [Epub ahead of print]. Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach. Sivaraj D et al. Clin Lymphoma Myeloma Leuk. 2016 Mar 29. pii:…Details
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. Moreau P et al. N Engl J Med. 2016 Apr 28;374(17):1621-1634. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractorymultiple myeloma: dose selection for a phase 3 maintenance study. Gupta N et al. Invest New Drugs. 2016 Apr 2. [Epub ahead of print]. Phase 1 Clinical Trial of Marizomib (NPI-0052) in Patients…Details
Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease. Fu J et al. J Clin Invest. 2016 Apr 4. pii: 80276. doi: 10.1172/JCI80276. [Epub ahead of print]. Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients. Bieghs L et al. PLoS One. 2016 Apr 25;11(4):e0154256. doi: 10.1371/journal.pone.0154256. eCollection 2016. Assessment of tumoral plasma cells in apheresis products for autologous stem…Details
Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. Martino M et al. Bone Marrow Transplant. 2016 Apr 4. doi: 10.1038/bmt.2016.79. [Epub ahead of print]. Nuances in the Management of Older People With Multiple Myeloma. Pawlyn C et al. Curr Hematol Malig Rep. 2016 Apr 2. [Epub ahead of print]. Management of multiple myeloma in older adults: Gaining ground with…Details
Local radiotherapy for palliation in multiple myeloma patients with symptomatic bone lesions.
Lee JW et al. Radiat Oncol J. 2016 Mar;34(1):59-63. doi: 10.3857/roj.2016.34.1.59. Epub 2016 Mar 30.
(003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Contr(Sol and Decreases Time to Chemotherapy
[No authors listed] Oncology (Williston Park). 2016 Apr 11;30(4 Suppl 1). pii: 216627.
Engraftment syndrome manifesting as acute brachial neuropathy following high-dose chemotherapy for management of plasma cell myeloma. Ninkovic S et al. Leuk Lymphoma. 2016 Apr 27:1-4. [Epub ahead of print]. A predictive tool particularly designed for elderly myeloma patients presenting with spinal cord compression. Rades D et al. BMC Cancer. 2016 Apr 25;16(1):292. doi: 10.1186/s12885-016-2325-y. A multicenter, retrospective epidemiologic survey of the clinical features and…Details
A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy. Martino M et al. Bone Marrow Transplant. 2016 Apr 18. doi: 10.1038/bmt.2016.94. [Epub ahead of print]. Comparison between intermittent and continuous spectra optia leukapheresis systems for autologous peripheral blood stem cell collection.…Details